724 results on '"Zambello, R"'
Search Results
2. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma
3. P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
4. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: STAT3 MUTATIONS IMPACT ON MDS ASSOCIATION IN PATIENTS WITH LGL LEUKEMIA (LGLL)
5. P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE
6. P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
7. P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
8. P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
9. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients
10. P069 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: STAT3 MUTATIONS IMPACT ON MDS ASSOCIATION IN PATIENTS WITH LGL LEUKEMIA (LGLL)
11. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
12. P600: HIGH-DEPTH RNA-SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T-LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY
13. P605: T-CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY
14. P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
15. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
16. Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
17. P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
18. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
19. Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2
20. P02 - Topic: AS01-Diagnosis/AS01b-Flow cytometry: INCIDENCE AND RELEVANCE OF T-LARGE GRANULAR LYMPHOCYTES AND NK CELLS IMBALANCES IN BONE MARROW BLOOD IN MYELODYSPLASTIC SYNDROMES
21. O19 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: A MULTI-CENTER EXPERIENCE OF HYPOCELLULAR MYELODYSPLASTIC SYNDROMES (H-MDS): FROM CLINICAL DESCRIPTION TO IMMUNOLOGICAL CHARACTERIZATION
22. Topic: AS01-Diagnosis/AS01b-Flow cytometry
23. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
24. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells
25. Clinical spectrum of γδ+ T cell LGL leukemia: Analysis of 20 cases
26. OPEN: Cyclophosphamide as a first-line therapy in LGL leukemia
27. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes
28. The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes
29. State of the art in natural killer cell malignancies
30. High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial: P859
31. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451
32. A Phase III Study of VMPT Versus VMP in Newly Diagnosed Elderly Myeloma Patients: A117
33. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
34. T-cell receptor molecular analysis in paediatric patients undergoing allogenic bone marrow transplantation
35. Role of NK alloreactivity in matched unrelated donor bone marrow transplantation in lymphoid neoplasia: single-centre experience
36. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
37. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
38. Rituximab-responsive CIDP
39. Identification of a miR-146b-FasL axis in the development of neutropenia in T-LGL leukemia
40. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
41. TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)
42. BORTEZOMIB LOWERS THE STAT3 PATHOGENETIC ROLE IN T-LGLL NEUTROPENIA DEVELOPMENT BY RESTORING MIR146B EXPRESSION
43. PF364 BORTEZOMIB LOWERS THE STAT3 PATHOGENETIC ROLE IN T-LGLL NEUTROPENIA DEVELOPMENT BY RESTORING MIR146B EXPRESSION
44. PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS
45. PF367 MOLECULAR EVIDENCE THAT ATOVAQUONE IS A NEW STAT3-INHIBITOR COUNTERBALANCING LEUKEMIC CELL PRO-SURVIVAL IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA
46. PS1140 THE IMBALANCE OF THE NON-LEUKEMIC COMPARTMENT SUSTAINS THE LYMPHOPROLIFERATION IN T-LARGE GRANULAR LYMPHOCITYES LEUKEMIA
47. CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS
48. LONG-TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT)
49. PF362 A FIRST HIGH-DEFINITION LANDSCAPE OF SOMATIC MUTATIONS IN CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS
50. PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.